Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults

Clinical Microbiology and Infection

Volumn 19, Issue SUPPL.1, 2013, Pages 1-9

  Durando, P ^a   Faust, S N ^b   Fletcher, M ^c   Krizova, P ^d   Torres, A ^e   Welte, T ^f  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c PFIZER INC   (United States)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adult vaccination; Burden of disease; Community acquired pneumonia; Invasive pneumococcal disease; Pneumococcal conjugate vaccines; Pneumococcal disease; Vaccine

Indexed keywords

AMOXICILLIN; CARRIER PROTEIN; DIPHTHERIA TOXOID CRM197; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; HERD; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INCIDENCE; MICROBIOLOGY; MORTALITY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; WHOLE CELL;

STREPTOCOCCUS PNEUMONIAE;

ADULT VACCINATION; BURDEN OF DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; INVASIVE PNEUMOCOCCAL DISEASE; PNEUMOCOCCAL CONJUGATE VACCINES; PNEUMOCOCCAL DISEASE; VACCINE;

ADULT; BACTERIAL PROTEINS; CHILD; EUROPE; HUMANS; IMMUNIZATION PROGRAMS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; POPULATION SURVEILLANCE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84884954728     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12320     Document Type: Article

References (61)

1. World Health Organization. Acute Respiratory Infections (Update September 2009). Available from: http://www.who.int/vaccine_research/diseases/ari/en/index3.html (last accessed 12 December 2011).
2. Krueger P, St Amant O, Loeb M. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study. BMC Geriatr 2010; 10: 44.
3. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine preventable diseases. The pink book, 11th edn. Washington, DC: Public Health Foundation, 2009.
4. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC, 2011.
5. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
6. McIntosh ED, Fritzell B, Fletcher MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect 2007; 135: 644-656.
7. European Centre for Disease Prevention and Control. Annual epidemiological report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data. Sweden: Stockholm, 2012.
8. O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
9. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009; 30: 127-135.
10. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79.
11. World Health Organization. Ageing and Life Course. Available from http://www.who.int/ageing/en/ (last accessed 24 October 2012).
12. Wroe PC, Finkelstein JA, Ray GT et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012; 205: 1589-1592.
13. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010; 28: 4955-4960.
14. Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans. Clin Microbiol Infect 2012; 18: 15-24.
15. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-819.
16. European Medicines Agency. Summary of opinion (post authorisation). Prevenar 13. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001104/WC500112838.pdf (last accessed 24 October 2012).
17. European Medicines Agency. Assessment report - Prevenar 13 pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Procedure No.: EMEA/H/C/001104/II/0028. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500119784.pdf (last accessed 6 January 2012).
18. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9: 213-220.
19. Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 2011; 17: 1602-1609.
20. World Health Organization. Pneumococcal vaccines WHO position paper - 2012. Wkly Epidemiol Rec 2012; 87: 129-144.
21. Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Ann N Y Acad Sci 2012; 1263: 15-26.
22. EUVac.Net. Pneumococcal vaccination (PCV) overview in European countries. Available from http://www.euvac.net/graphics/euvac/vaccination/pcv.html (last accessed 24 October 2012).
23. Myint TH, Madhava H, Balmer P et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013; 30: 127-151.
24. PediSurv. Surveillance of infectious diseases in children in Belgium [Surveillance des maladies infectieuses chez les enfants en Belgique]. https://www.wiv-isp.be/pedisurv/f_index.htm (last accessed 28 November 2012).
25. van der Linden M, Weiss S, Falkenhorst G, Siedler A, Imohl M, von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012; 30: 5880-5885.
26. Rodenburg GD, de Greeff SC, Jansen AG et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010; 16: 816-823.
27. Vestrheim DF, Hoiby EA, Bergsaker MR, Ronning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine 2010; 28: 2214-2221.
28. Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010; 65: 770-774.
29. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 1179-1186.
30. Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA. Trends in otitis media treatment failure and relapse. Pediatrics 2008; 121: 674-679.
31. Smith PJ, Nuorti JP, Singleton JA, Zhao Z, Wolter KM. Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey. Pediatrics 2007; 120: e1165-e1173.
32. Dowell SF, Butler JC, Giebink GS. Acute otitis media: management and surveillance in an era of pneumococcal resistance. Drug-Resistant Streptococcus Pneumoniae Therapeutic Working Group. Nurse Pract 1999; 24: 1-9; quiz 15-16.
33. Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007; 161: 1162-1168.
34. Stamboulidis K, Chatzaki D, Poulakou G et al. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J 2011; 30: 551-555.
35. Durando P, Crovari P, Ansaldi F et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27: 3459-3462.
36. Gisselsson-Solén M, Melhus Å, Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media - a randomized study. Acta Paediatr 2011; 100: 1354-1358.
37. Madhi SA, Klugman KP; The Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811-813.
38. Spijkerman J, van Gils EJM, Veenhoven RH et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis 2011; 17: 584-591.
39. Tocheva AS, Jefferies JM, Rubery H et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 2011; 29: 4400-4404.
40. Ansaldi F, de Florentiis D, Canepa P et al. Carriage of Streptoccoccus pneumoniae 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy. Vaccine 2012; 30: 2288-2294.
41. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28: 4249-4259.
42. van Gils EJM, Veenhoven RH, Hak E et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010; 304: 1099-1106.
43. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760-768.
44. Fenoll A, Granizo JJ, Aguilar L et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47: 1012-1020.
45. Foster D, Walker AS, Paul J et al. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol 2011; 60: 91-97.
46. Guevara M, Barricarte A, Gil-Setas A et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009; 15: 1013-1019.
47. Hanna JN, Humphreys JL, Murphy DM, Smith HV. Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001-2009. Med J Aust 2010; 193: 392-396.
48. Lehmann D, Willis J, Moore HC et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010; 50: 1477-1486.
49. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297: 1784-1792.
50. van Deursen AM, van Mens SP, Sanders EA et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 2012; 18: 1729-1737.
51. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962-1973.
52. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29: 9127-9131.
53. Bettinger JA, Scheifele DW, Kellner JD et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010; 28: 2130-2136.
54. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14: e197-e209.
55. Ingels H, Rasmussen J, Andersen PH et al. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine 2012; 30: 3944-3950.
56. Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66: 378-383.
57. French N, Gordon SB, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812-822.
58. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, Issue (1). Art. No.: CD000422. DOI: 10.1002/14651858.CD000422.pub3
59. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206.
60. McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011; 10: 109-129.
61. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 83: 373-384.